Psychedelic Spotlight | Covering The Emerging Psychedelics Industry

From May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here's why that matters for the psychedelics industry.

I finally caught the bug, and after a mild bout with the Coronavirus, I ate 3.7 grams of mushrooms during my final weekend of quarantine.

Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.

The history of MDMA is fascinating, and it is still being written.

This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.

This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.

Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.

Psychedelic advocates are preparing to present Illinois' first-ever policy reform bill, but before they do, they need public support.

Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.

This week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022.

Watch late psychedelic icons María Sabina and Terence McKenna in action, and catch a glimpse inside psilocybin therapy sessions.

Psychedelic Spotlight's video producer attended the inaugural Benzinga Psychedelic Capital Conference, and here's what he walked away with.

Another Michigan city decriminalizes psychedelic plants and fungi, while Maryland passes a bill to provide military veterans with cost-free access to healing medicines like ketamine, psilocybin, and MDMA.

Researchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.

Psychiatrist, researcher, and CEO of Zylorion Health, Dr. Peter Silverstone, ranks psychedelic medicines based on their potential to revolutionize mental health treatment.

Latest News

psycspotlight